Cannabis use among IBD patients more than doubled after Canadian legalization
In a Canadian tertiary care center, 41% of Crohn's disease and 31% of ulcerative colitis patients reported recent cannabis use, rates that have more than doubled since legalization, yet cannabis users had worse symptoms and quality of life.
Quick Facts
What This Study Found
Recent cannabis use was reported by 41% of Crohn's disease patients and 31% of ulcerative colitis patients, more than double pre-legalization rates of ~16% and ~12% respectively. Cannabis users reported more abdominal pain, poor appetite, and flatulence, with lower quality of life scores (SIBDQ 37 vs 40). Less than half (46%) discussed cannabis with their physician.
Key Numbers
254 participants (148 CD, 90 UC, 16 indeterminate); 41% CD and 31% UC recent cannabis use; pre-legalization rates ~16% CD and ~12% UC; cannabis users SIBDQ 37 vs non-users 40; only 46% discussed with physician
How They Did This
Prospective cohort study of 254 IBD patients at a Canadian tertiary care center who completed online surveys covering demographics, disease history, cannabis use, and the Short IBD Questionnaire (SIBDQ).
Why This Research Matters
The dramatic increase in cannabis use among IBD patients after legalization, combined with worse symptoms in users and low rates of physician discussion, represents a clinical blind spot.
The Bigger Picture
The finding that cannabis users had worse symptoms and quality of life, despite using cannabis ostensibly for symptom relief, raises questions about whether cannabis is genuinely helping or whether sicker patients are simply more likely to try it.
What This Study Doesn't Tell Us
Cross-sectional design cannot determine causation; tertiary care center patients may have more severe disease; self-reported cannabis use; pre-legalization comparison from different study populations; no data on cannabis type, dose, or frequency
Questions This Raises
- ?Are IBD patients using cannabis because their symptoms are worse, or is cannabis contributing to worse symptoms?
- ?Would structured cannabis counseling by gastroenterologists improve outcomes?
Trust & Context
- Key Stat:
- 41% of Crohn's patients using cannabis post-legalization
- Evidence Grade:
- Single-center prospective survey with validated quality of life measure, but cross-sectional design and tertiary care setting limit generalizability.
- Study Age:
- 2024 study
- Original Title:
- Cannabis Use in Patients With Inflammatory Bowel Disease Following Legalization of Cannabis in Canada.
- Published In:
- Crohn's & colitis 360, 6(2), otae031 (2024)
- Authors:
- Iablokov, Vadim, Gregor, Jamie, Chande, Nilesh, Ponich, Terry, Jairath, Vipul, Khanna, Reena, Asfaha, Samuel
- Database ID:
- RTHC-05395
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
How much did IBD cannabis use increase after legalization?
Cannabis use roughly doubled or more: 41% of Crohn's disease patients and 31% of ulcerative colitis patients reported recent use, compared to pre-legalization estimates of about 16% for CD and 12% for UC from US studies.
Did cannabis help IBD symptoms?
Cannabis users actually reported worse outcomes: more abdominal pain, poor appetite, and flatulence, along with lower quality of life scores. However, this could reflect sicker patients being more likely to try cannabis rather than cannabis causing the symptoms. Only 46% of users discussed cannabis with their doctor.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05395APA
Iablokov, Vadim; Gregor, Jamie; Chande, Nilesh; Ponich, Terry; Jairath, Vipul; Khanna, Reena; Asfaha, Samuel. (2024). Cannabis Use in Patients With Inflammatory Bowel Disease Following Legalization of Cannabis in Canada.. Crohn's & colitis 360, 6(2), otae031. https://doi.org/10.1093/crocol/otae031
MLA
Iablokov, Vadim, et al. "Cannabis Use in Patients With Inflammatory Bowel Disease Following Legalization of Cannabis in Canada.." Crohn's & colitis 360, 2024. https://doi.org/10.1093/crocol/otae031
RethinkTHC
RethinkTHC Research Database. "Cannabis Use in Patients With Inflammatory Bowel Disease Fol..." RTHC-05395. Retrieved from https://rethinkthc.com/research/iablokov-2024-cannabis-use-in-patients
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.